COMPASS Pathways plc (CMPS) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Care Facilities secteur d'activité. Le siège social de l'entreprise est situé à London, United Kingdom. Le PDG actuel est Kabir Kumar Nath.
CMPS a date d'introduction en bourse 2020-09-18, 166 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $572.67M.
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
